BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Proposed Acquisition Further Positions it to Aid Efforts to Accelerate Discovery of New Anti-Cancers, Anti-Virals and Vaccines

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today provided an update on its proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine. According to the update, this move further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines. The acquisition will provide POAI with QM’s exclusively licensed, proven machine learning framework (“CoRE”), developed at CMU. CoRE, a predictive model-building platform for drug screening and optimization campaigns, uses hybrid machine learning approaches to rapidly build predictive models to drive wet lab experimentation. The CoRE approach united with POAI-Helomics division’s PDx tumor profiling platform and tumor data database allows for a one-of-a-kind, end-to-end “discovery machine” to cost-effectively and rapidly generate potential therapeutic candidates, which can be fast-tracked with demonstrated activity in preclinical laboratory tests. In projects with pharmaceutical companies, QM demonstrated that the CoRE platform could reduce time by 50% in the discovery of novel therapeutics. This “speed-to-patient” is important not only in cancer and other diseases but vital when searching for treatments or vaccines for a novel virus such as the coronavirus 2019-nCoV.

To view the full press release, visit http://nnw.fm/10jRP

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.